Study
PLCO
(Learn more about this study)
Project ID
2013-0041
Initial CDAS Request Approval
May 1, 2013
Title
An integrative validation study of circulating glycans, metabolites, lipids, autoantibodies and proteins as biomarkers for lung cancer early detection
Summary
Lung cancer is the leading cause of cancer death among men and the second leading cause among women worldwide. Findings from the recent NLST study indicate that low-dose CT screening reduced lung cancer mortality. However, there remains a need for biomarkers to identify subjects at risk and for early detection of lung cancer. Based on integrative analysis of data from several quantitative serum profiling platforms (glycomics, metabolomics, immunomics, and proteomics), we have identified a set of circulating biomarker candidates that in initial validation studies, can discriminate between pre-diagnostic sera from lung cancer subjects from control subjects. The main goal of our proposed PLCO study is to determine if our candidate biomarkers also can detect cancer before clinical diagnosis in an independent, pre-diagnostic sample cohort and to determine marker performance in relation to time to diagnosis, so that we can move forward to prospective screening studies. Therefore serum samples from PLCO trial are the most suitable sample set for our proposed study.
Aims
Based on integrative analysis of data from multiple quantitative serum profiling platforms (glycomics, metabolomics, immunomics, and proteomics), that we have applied to aliquots from the same cohort samples for initial discovery and validation, we have identified a set of circulating biomarker candidates that can discriminate pre-diagnostic sera from cancer subjects and from control subjects. The main goal of our proposed study is to determine if our candidate biomarkers also can detect cancer before clinical diagnosis in an independent, pre-diagnostic sample cohort and to determine marker performance in relation to time to diagnosis.
Collaborators
Samir Hanash (The University of Texas MD Anderson Cancer Center)
Ziding Feng (Fred Hutchinson Cancer Research Center)
David Gandara (University of California, Davis)
Oliver Fiehn (University of California, Davis)
Carlito Lebrilla (University of California, Davis)
Suzanne Miyamoto (University of California, Davis)
